Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables RefundsShares IssuedShares OutstandingShares Outstanding
Ratios

Sangamo Therapeutics (SGMO) Leases (2019 - 2025)

Sangamo Therapeutics has reported Leases over the past 7 years, most recently at $3.1 million for Q4 2025.

  • For Q4 2025, Leases fell 81.84% year-over-year to $3.1 million; the TTM value through Dec 2025 reached $3.1 million, down 81.84%, while the annual FY2025 figure was $3.1 million, 81.84% down from the prior year.
  • Leases for Q4 2025 was $3.1 million at Sangamo Therapeutics, down from $14.4 million in the prior quarter.
  • Over five years, Leases peaked at $73.2 million in Q4 2021 and troughed at $3.1 million in Q4 2025.
  • A 5-year average of $40.8 million and a median of $37.0 million in 2023 define the central range for Leases.
  • Biggest five-year swings in Leases: grew 3.01% in 2021 and later crashed 81.84% in 2025.
  • Year by year, Leases stood at $73.2 million in 2021, then fell by 15.28% to $62.0 million in 2022, then plummeted by 58.08% to $26.0 million in 2023, then tumbled by 35.1% to $16.9 million in 2024, then crashed by 81.84% to $3.1 million in 2025.
  • Business Quant data shows Leases for SGMO at $3.1 million in Q4 2025, $14.4 million in Q3 2025, and $15.1 million in Q2 2025.